The findings have clear implications for TRAF3IP3 as biomarkers in predicting the prognosis of patients with HBV-related HCC, and they provide new research directions as well as diagnostic and treatment options for this condition. Here, TRAF3IP3 is linked to hepatocellular carcinoma.